Mode
Text Size
Log in / Sign up
Phase 2 N=38 Treatment

Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections

Diabetic Foot Infections

Enrolled (actual)
38
Serious AEs
13.2%
Results posted
Jan 2015
Primary outcome: Primary: Clinical Success (in ITT Population) — 95.7 percentage of participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
TG-873870 (Nemonoxacin) (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
TaiGen Biotechnology Co., Ltd.
Primary completion
Apr 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Clinical Success (in ITT Population)
95.7
SECONDARY
Microbiological Success Rate
82.6; 89.5
SECONDARY
Clinical Success (in PP Population)
94.7
SECONDARY
Clinical Success (at End of Treatment/Early Termination)
100.0; 100.0
SECONDARY
Per-Pathogen Clinical Responses (at Test of Cure)
100.0; 100.0; 100.0; 100.0; 100.0; 100.0
SECONDARY
Per-Pathogen Clinical Response (at End of Treatment/Early Termination)
100.0; 100.0; 100.0; 100.0; 100.0; 100.0
SECONDARY
Per-Pathogen Microbiological Responses
93.3; 100.0; 66.7; 75.0; 75.0; 75.0
SECONDARY
Total Wound Score (at Test of Cure in ITT Population)
16.9; 6.0; -11.2
SECONDARY
Total Wound Score (at Test of Cure in PP Population)
18.2; 5.0; -12.9
SECONDARY
Total Wound Score (at End of Treatment/ Early Termination in ITT Population)
16.9; 7.2; -9.6
SECONDARY
Total Wound Score (at End of Treatment/ Early Termination in PP Population)
18.2; 6.2; -12.1
SECONDARY
Diabetic Foot Assessment (PEDIS) Shifts From Baseline at End of Treatment/Early Termination in ITT Population
0; 0; 0; 0; 8; 4
SECONDARY
Diabetic Foot Assessment (PEDIS) Shifts From Baseline at Test of Cure in ITT Population
0; 0; 0; 0; 8; 2
SECONDARY
Diabetic Foot Assessment (PEDIS) Shifts From Baseline at End of Treatment/Early Termination in PP Population
0; 0; 0; 0; 6; 1
SECONDARY
Diabetic Foot Assessment (PEDIS) Shifts From Baseline at Test of Cure in PP Population
0; 0; 0; 0; 6; 1
SECONDARY
Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in ITT Population)
1; 1; 3
SECONDARY
Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in ITT Population)
1; 1; 3
SECONDARY
Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in PP Population)
0; 0; 1
SECONDARY
Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in PP Population)
0; 0; 1

Summary

Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections

Eligibility Criteria

Inclusion Criteria

  • Body weight ≥ 40 kg
  • Previously known or newly diagnosed diabetes mellitus, including type 1 and type 2 (per the American Diabetes Association guidelines), which is controlled by proper lifestyle (diet, exercise) or treatment with either oral medications or insulin
  • Patients' HbA1c ≦ 12% at screening
  • Clinically defined diabetic foot infection of mild or moderate severity (PEDIS grade 2-3) as based on the guideline of the Infectious Diseases Society of America. It includes any inframalleolar infection of the soft-tissue, such as paronychia, cellulitis, myositis, abscesses, and tendonitis
  • Evidence of necrotic tissue, purulent collections or abscess that may require excision, incision or drainage (based on investigator's judgment, and a surgeon if needed)
  • Must be able to provide suitable tissue specimens (preferably obtained by biopsy or tissue curettage, or purulent fluid aspiration, rather than by swabbing) from the infected wound (after appropriate cleansing and debridement) for Gram-staining and bacterial cultures (aerobes and anaerobes)
  • A confirmed Gram-positive pathogen infection by Gram-stain. The criterion to determine patient's eligibility for study recruitment is a Gram-stained smear with at least 1 Gram-positive organism seen in at least two high power fields. A solely Gram-positive pathogen infection or a polymicrobial infection including Gram-positive and Gram-negative pathogens are acceptable within the framework of the study

Exclusion Criteria

  • A co-morbid disease condition that could compromise evaluation or participation in this study, such as severe hepatic disease (e.g., active hepatitis, decompensated liver cirrhosis), renal failure (estimated creatinine clearance [CrCl] 20 mg/day of prednisone, or its equivalent)
  • Has received or will be receiving chemotherapy or oncolytics within six months prior to entering or during the study
  • History of current or active alcohol abuse (>3 drinks daily or binge drinking) or any illicit drug use
  • Known or suspected critical ischemia of the affected limb (based on investigators' clinical judgments and vascular assessment)
  • Wound that contains or is proximate to any prosthetic materials or devices that is/are not scheduled for removal
  • Patient with a foot infection that, in the investigator's judgment, is severe enough to require hospitalization or intravenous antibiotic therapy
  • Neutrophil count <1000 cells/mm3
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00685698). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search